We are live on
!
Find out more
BCM
Boone Capital Management Portfolio holdings
AUM
$326M
1-Year Est. Return
86.31%
This Fund
S&P 500
This Quarter
Est. Return
+3.12%
1 Year Est. Return
+86.31%
3 Year Est. Return
+255.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$326M
AUM Growth
+$7.8M
(+2.4%)
Cap. Flow
+$4.33M
Cap. Flow
% of AUM
1.33%
Top 10 Holdings %
Top 10 Hldgs %
90.65%
Holding
19
New
4
Increased
5
Reduced
2
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teleflex
TFX
|
+$30.7M |
| 2 |
GRDN
Guardian Pharmacy Services
GRDN
|
+$20.6M |
| 3 |
AVNS
Avanos Medical
AVNS
|
+$16M |
| 4 |
Cigna
CI
|
+$11.4M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$7.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$21.5M |
| 2 |
HealthEquity
HQY
|
+$19.5M |
| 3 |
LivaNova
LIVN
|
+$17.8M |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$15.9M |
| 5 |
Tyra Biosciences
TYRA
|
+$10.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$6.46B
| $38.9M | 11.92% |
421,236
| – | – |
|
2
Ionis Pharmaceuticals
IONS
$8.6B
| $37.6M | 11.51% |
500,522
+82,689
| +20% | +$6.53M |
|
|
3
Cigna
CI
$73.8B
| $36.7M | 11.24% |
137,522
+41,069
| +43% | +$11.4M |
|
4
Medtronic
MDT
$109B
| $34.5M | 10.57% |
398,065
-30,724
| -7% | -$2.94M |
|
|
5
Teleflex
TFX
$6.05B
| $33.3M | 10.22% |
+278,792
| New | +$30.7M |
|
|
6
BioMarin Pharmaceuticals
BMRN
$11.6B
| $30.9M | 9.48% |
547,871
+135,991
| +33% | +$7.93M |
|
|
GRDN
7
Guardian Pharmacy Services
GRDN
$2.5B
| $23.8M | 7.28% |
+631,193
| New | +$20.6M |
|
8
AstraZeneca
AZN
$263B
| $21.7M | 6.65% |
110,101
| – | – |
|
9
UnitedHealth
UNH
$376B
| $21.4M | 6.57% |
79,226
+17,464
| +28% | +$5.2M |
|
10
BridgeBio Pharma
BBIO
$15.7B
| $17M | 5.21% |
228,829
+43,866
| +24% | +$3.18M |
|
|
AVNS
11
DELISTED
Avanos Medical
AVNS
| $16.6M | 5.09% |
+1,184,909
| New | +$16M |
|
12
Kodiak Sciences
KOD
$2.6B
| $10.7M | 3.29% |
281,332
-222,498
| -44% | -$5.75M |
|
13
Tenax Therapeutics
TENX
$363M
| $3.2M | 0.98% |
+200,000
| New | +$2.71M |
|
|
14
HealthEquity
HQY
$8.41B
| – | – |
-212,856
| Closed | -$19.5M |
|
|
15
LivaNova
LIVN
$4.4B
| – | – |
-288,895
| Closed | -$17.8M |
|
|
16
Neurocrine Biosciences
NBIX
$16.8B
| – | – |
-151,815
| Closed | -$21.5M |
|
|
RAPT
17
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-470,456
| Closed | -$15.9M |
|
|
18
Tyra Biosciences
TYRA
$1.9B
| – | – |
-398,482
| Closed | -$10.5M |
|
19
Wave Life Sciences
WVE
$1.09B
| – | – |
-352,144
| Closed | -$5.99M |
|
Similar funds
ISFAN
JHWEPV
AFA
ECH
DCM
MVM
CCG
TC
Boone Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Boone Capital Management held 19 positions worth $326M, up 2.4% from $319M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Boone Capital Management's Q1 2026 filing shows 4 new, 5 increased, 2 reduced and 6 closed positions. Its largest new stake was Teleflex: 278,792 shares worth $33.3M. The largest sale was Neurocrine Biosciences, an estimated $21.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Boone Capital Management's largest Q1 2026 buy was Teleflex: 278,792 shares worth $33.3M.
- Boone Capital Management added most to Cigna in Q1 2026, an estimated $11.4M increase.
- Boone Capital Management's biggest Q1 2026 reduction was Kodiak Sciences, cutting an estimated $5.75M.
- Boone Capital Management fully exited Neurocrine Biosciences in Q1 2026, selling an estimated $21.5M.
- Boone Capital Management's ten largest holdings make up 91% of its $326M portfolio in Q1 2026.
- Boone Capital Management opened 4 new positions and closed 6 in Q1 2026.
- Boone Capital Management's portfolio value rose 2.4% quarter-over-quarter to $326M.
Based on Boone Capital Management's 13F filing for Q1 2026, filed 15 May 2026.